Background: It has been suggested that mild cognitive impairment (MCI) can be used to identify patients at risk of developing clinical stages of Alzheimer’s disease (AD).
Objective: The aim of this study was to describe the characteristics of amnesic syndrome of dementia of the Alzheimer’s type (DAT) as a continuous degenerative process from normality to amnesic syndrome and provide a classification of the degrees of amnesia.
Methods: Of 3,800 new incidental cases at the Memory Clinic, 747 were classified as non-demented patients. A 96-month follow-up study was conducted. We described and compared longitudinal outcomes from normality to amnesic syndrome based on immediate memory, verbal learning, free recall, and recognition using the memory scale from the Basic Neuropsychological Battery, version D (BNB-D) and created a new classification of memory impairment.
Results: Based on differences observed in this longitudinal study, we classified patients in four memory stages: M1, Normal episodic memory; M2, mild impairment in learning and/or free recall; M3, clear impairment in learning and/or free recall; and M4, complete amnesic syndrome. With this new amnesia classification, we studied the chronological progression of all patients diagnosed without dementia from baseline to DAT conversion using the Kaplan-Meier estimator of survival probability (Log Rank/Mantel Cox comparison. χ2 = 171.84, p = 0.001).
Conclusion: This new classification of memory impairment can help increase the prediction certainty of conversion from amnestic MCI to AD and improve research on AD biomarkers and their relationship with memory as the principal manifestation of AD.
KralVA (1962) Senescent forgetfulness: Benign and malignant. Can Med Assoc J86, 257–260.
7.
CrookTJ, BartusR, FerrisSH, WhitehouseP, CohenGD, GershonS (1986) Age-associated memory impairment: Proposed diagnostic criteria and measures of clinical change, report of a national institute of mental health work group. Dev Neuropsychol2, 261–276.
8.
LevyR (1994) Aging-associated cognitive decline. Working party of the international psychogeriatric association in collaboration with the World Health Organization. Int Psychogeriatr6, 63–68.
9.
American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th ed. American Psychiatric Association, Washington, DC.
SperlingRA, AisenPS, BeckettLA, BennettDA, CraftS, FaganAM, IwatsuboT, JackCRJr, KayeJ, MontineTJ, ParkDC, ReimanEM, RoweCC, SiemersE, SternY, YaffeK, CarrilloMC, ThiesB, Morrison-BogoradM, WagsterMV, PhelpsCH (2011) Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 280–292.
12.
ModregoPJ (2006) Predictors of conversion to dementia of probable Alzheimer type in patients with mild cognitive impairment. Curr Alzheimer Res3, 161–170.
13.
RabinLA, PareN, SaykinAJ, BrownMJ, WishartHA, FlashmanLA, SantulliRB (2009) Differential memory test sensitivity for diagnosing amnestic mild cognitive impairment and predicting conversion to Alzheimer’s disease. Neuropsychol Dev Cog B Aging Neuropsychol Cog16, 357–376.
14.
RountreeSD, WaringSC, ChanWC, LupoPJ, DarbyEJ, DoodyRS (2007) Importance of subtle amnestic and nonamnestic deficits in mild cognitive impairment: Prognosis and conversion to dementia. Dement Geriatr Cogn Disord24, 476–482.
15.
TremontG, MieleA, SmithMM, WesterveltHJ (2010) Comparison of verbal memory impairment rates in mild cognitive impairment. J Clin Exp Neuropsychol32, 630–636.
16.
AlbertMS, DeKoskyST, DicksonD, DuboisB, FeldmanHH, FoxNC, GamstA, HoltzmanDM, JagustWJ, PetersenRC, SnyderPJ, CarrilloMC, ThiesB, PhelpsCH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 270–279.
TulvingE (1995) Organization of memory: Quo vadis? In The Cognitive Neurosciences, GazzanigaM, ed. MIT Press, Cambridge, pp. 839–847
.
19.
Van der LindenM, BruyerR (1991) Neuropsychologie de la mémoire humane. Presses Universitaires de Grenoble, Edisem Grenoble.
20.
LussierI, MalenfantD, PeretzI, BelevilleS (1991) Caractérisation des troubles de la mémoire dans la démence de type Alzheimer. In Démences et syndromes démentiels: Approche neuropsychologique, Dans HabibM, JoanetteY, PuelM, eds. Masson, Paris.
21.
GainottiG, MarraC, VillaG, ParlatoV, ChiarottiF (1998) Sensitivity and specificity of some neuropsychological markers of Alzheimer dementia. Alzheimer Dis Assoc Disord12, 152–162.
22.
WeintraubS, WicklundAH, SalmonDP (2012) The neuropsychological profile of Alzheimer disease. Cold Spring Harb Perspect Med2, a006171.
23.
BucknerRL, WheelerME (2001) The cognitive neuroscience of remembering. Nat Rev Neurosci2, 624–634.
24.
FarovikA, DupontLM, ArceM, EichenbaumH (2008) Medial prefrontal cortex supports recollection, but not familiarity, in the rat. J Neurosci28, 13428–13434.
25.
BradfordCD, SperlingRA (2008) Functional abnormalities of the medial temporal lobe memory system in mild cognitive impairment and Alzheimer’s disease: Insights from functional MRI studies. Neuropsychologia46, 1624–1635.
DelacourteA, DavidJP, SergeantN, BuéeL, WattezA, VermerschP, GhozaliF, Fallet-BiancoC, PasquierF, LebertF, PetitH, Di MenzaC (1999) The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer’s disease. Neurology52, 1158–1165.
35.
Llorente-VizcainoA, Cejudo-BolivarJC (2001) Las memorias y la enfermedad de Alzheimer. Rev Neurol32, 1163–1172.
36.
GainottiG, QuarantaD, VitaMG, MarraC (2014) Neuropsychological predictors of conversion from mild cognitive impairment to Alzheimer’s disease. J Alzheimers Dis38, 481–495.
37.
DonohueMC, SperlingRA, SalmonDP, RentzDM, RamanR, ThomasRG, WeinerM, AisenPS, Australian Imaging Biomarkers, and Lifestyle Flagship Study of Ageing; Alzheimer’s Disease Neuroimaging Initiative; Alzheimer’s Disease Cooperative Study
(2014) The preclinical Alzheimer cognitive composite: Measuring amyloid-related decline. JAMA Neurol71, 961–970.
38.
RochonPA, GurwitzJH, SykoraK, MamdaniM, StreinerDL, GarfinkelS, NormandSL, AndersonGM (2005) Reader’s guide to critical appraisal of cohort studies: 1. Role and design. BMJ330, 895–897.
39.
McKhannG, DrachmanD, FolsteinM, KatzmanR, PriceD, StadlanEM (1984) Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology34, 939–944.
40.
ReisbergB, PrichepL, MosconiL, JohnER, Glodzik-SobanskaL, BoksayI, MonteiroI, TorossianC, VedvyasA, AshrafN, JamilIA, de LeonMJ (2008) The pre-mild cognitive impairment, subjective cognitive impairment stage of Alzheimer’s disease. Alzheimer Dement4(Suppl 1), S98–S108.
41.
PetersenRC (2004) Mild cognitive impairment as a diagnostic entity. J Intern Med256, 183–194.
42.
CejudoJC (2014) Creación, validación y normalización de una Batería Neuropsicológica para el uso clínico en enfermedades que cursan con demencia: Batería Neuropsicológica Básica-Demencias (BNB-D). Trabajo Máster ICACS. Dipòsit digital Universitat Autònoma de Barcelona (UAB).
